Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report)’s share price passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $11.23 and traded as low as $10.65. Innovent Biologics shares last traded at $10.65, with a volume of 1,620 shares traded.
Innovent Biologics Trading Up 10.0%
The stock’s fifty day moving average price is $12.42 and its 200-day moving average price is $11.23.
Innovent Biologics Company Profile
Innovent Biologics, Inc is a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of medicines for cancer, autoimmune diseases and metabolic disorders. The company develops biologic therapies, including monoclonal antibodies, antibody-drug conjugates and other advanced treatments, with the goal of providing innovative and more accessible medicines.
Its marketed portfolio includes sintilimab, an immunotherapy developed in collaboration with Eli Lilly and marketed in China under the brand name Tyvyt, as well as biosimilar and biologic products for oncology and immune-related conditions.
Further Reading
- Five stocks we like better than Innovent Biologics
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
